NASDAQ: APGEApogee Therapeutics Inc Stock
$21.30+0.62 (+3%)
Updated Sep 29, 2023
APGE Price
$21.30
Fair Value Price
N/A
Market Cap
$1.08B
52 Week Low
$18.99
52 Week High
$25.54
P/E
N/A
P/B
-16.76x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.27
Operating Cash Flow
N/A
Beta
-0.22
Next Earnings
Nov 29, 2023
Ex-Dividend
N/A
Next Dividend
N/A
APGE Overview
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how APGE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
APGE's short-term assets ($130.67M) exceed its short-term liabilities ($17.62M)
Short-term Liabilities Financials
APGE's short-term assets ($130.67M) exceed its long-term liabilities ($0.00)
Long-term Liabilities Financials
APGE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more APGE due diligence checks available for Premium users.
Be the first to know about important APGE news, forecast changes, insider trades & much more!
APGE News
Valuation
APGE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-16.76x
Industry
5.09x
APGE's financial health
Profit margin
Revenue
$0.0
Net Income
-$18.9M
Profit Margin
0%
Assets to liabilities
Assets
$130.7M
Liabilities
$17.6M
Debt to equity
-0.27
APGE's short-term assets ($130.67M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APGE's short-term assets ($130.67M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APGE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
APGE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.6M
Investing
$0.0
Financing
-$1.7M
APGE vs Biotech Stocks
Apogee Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.